Lv1
50 积分 2025-04-09 加入
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib
10天前
已完结
Risk of ocular adverse events with aromatase inhibitors
1个月前
已完结
Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
5个月前
已完结
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
8个月前
已完结
皖公网安备34019202002308
